卵泡刺激素受体及其靶向药物的研究进展  

Advances in follicle stimulating hormone receptor and its targeted drugs

作　　者：朱晨 杨润琳[2] 杨敏[1,2] 

机构地区：[1]南京医科大学第一附属医院放疗科,江苏南京210029 [2]江苏省原子医学研究所分子影像中心,江苏无锡214063

出　　处：《肿瘤》2014年第9期863-867,共5页Tumor

基　　金：国家自然科学基金资助项目(编号:81171399;81472749);江苏省医学重点人才培养资助项目(编号:RC2011095);江苏省临床医学科技专项资助项目(编号:BL2012031);江苏省科技支撑计划(编号:BE2012622;BE2014609);江苏省卫计委项目(编号:Q201406);无锡市社会发展项目(编号:CSZ0N1320)

摘　　要：卵泡刺激素受体(follicle stimulating hormone receptor,FSHR)是一种G蛋白偶联受体,仅在哺乳动物生殖系统中痕量表达。新近研究发现,FSHR在多种肿瘤(如前列腺癌、乳腺癌、肝癌和肾癌等)的血管内皮上高度表达,并在疾病的发展进程中发挥重要作用。因此,FSHR是肿瘤诊治的一个潜在的靶点。开发FSHR靶向药物将有利于肿瘤的诊断、靶向治疗及个体化方案的选择和预后的判定。本文就FSHR及其特异性配体的研究进展作一综述。Follicle stimulating hormone receptor （FSHR） belongs to the G protein-coupled receptor family and is only low-expressed in reproductive organs of mammals. Recent studies have shown that FSHR is overexpressed in vascular endothelium of multiple types of human tumors including prostate cancer, breast cancer, liver cancer and kidney cancer, etc, and it plays an important role in the progression of cancer. Thus, FSHR is a potential target for diagnosis and treatment of tumors. Development of drugs targeting FSHR is beneficial to diagnosis, targeted therapy, selection of individualized drug therapy and prognosis of tumors. This paper summarizes the advances in FSHR and its specific ligands.

关 键 词：肿瘤 卵泡刺激素 放射性核素显像 分子探针技术 

分 类 号：R730.4[医药卫生—肿瘤]